15 November 2020 in Terapevticheskii arkhiv
Leishmaniasis is a vector-born parasitic disease characterized by predominant cutaneous or visceral involvement with fever, hepatosplenomegaly and anemia. Leishmaniasis has relatively high prevalence in tropical and subtropical areas. Several sporadic and mostly imported cases are detected in Russian Federation. Nevertheless, some local incidents are noted in southern areas (Crimea, Dagestan). Lack of epidemiological alertness hampers confirmation of diagnosis and may lead to incorrect treatment. The article summarizes current state of knowledge in epidemiology, diagnostic approach and treatment of leishmaniasis. Particular clinical case is discussed.
13 May 2021 in Rheumatology Science and Practice
Liver involvement in systemic lupus erythematosus is common and in most cases clinical course is asymptomatic, that makes diagnosis difficult. Determination of the cause of the liver involvement is important to select treatment and to evaluate the prognosis of the disease.Theaimof the research was to characterize the clinical features of liver involvement in patients with systemic lupus erythematosus and identify the most significant clinical and laboratory parameters for the differential diagnosis of lupus hepatitis.Materials and methods. The study included 313 patients with systemic lupus erythematosus observed in the E.M. Tareev Clinic of Rheumatology, Internal Medicine and Occupational Diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University) in the period from 2001 to 2019. The verification of diagnosis of systemic lupus erythematosus was based on the criteria of the American College of Rheumatology (1997). Patients examination included complete blood count, biochemical and immunological blood tests and an abdominal ultrasonography. In 13 cases hepatic autoantibodies (ASMA, anti-LKM-1, LC-1, SLA-LP, AMA-M2) were analyzed, in 4 – magnetic resonance cholangiopancreatography and in 6 – liver biopsy were made.Results. Liver involvement were represented by an increase of liver enzymes in 58 (18.5%) cases. Chronic viral hepatitis C was diagnosed in 4 (1.3%) patients. Drug-induced hepatitis was found in 17 (5.4%) patients. Autoimmune liver diseases occured in 2 (0.6%) patients. In 2 (0.6%) patients, liver damage was associated with thrombotic microangiopathy (atypical hemolytic uremic syndrome, hereditary thrombophilia). In 15 (4.8%) cases, the most likely diagnosis was NAFLD. Lupus hepatitis was the most likely cause in 18 (5.7%) patients. Differential diagnosis in cases of liver involvement in patients with systemic lupus erythematosus requires assessment of risk factors for various liver diseases, age of the patients, level of liver enzymes, lupus activity, ultrasound signs of liver steatosis and secondary antiphospholipid syndrome.Determining the cause of the liver involvement for the patients with the systemic lupus erythematosus allows establishing better treatment tactic and improvement of the prognosis.
28 April 2023 in Rheumatology Science and Practice
Objective – to evaluate the long-term outcomes of HCV eradication with direct-acting antivirals (DAAs) in patients with hepatitis C-associated cryoglobulinemic vasculitis (HCV-CV)Materials and methods. We retrospectively assessed 48 patients with HCV-CV treated with DAAs. The activity of HCV-CV was assessed by using Birmingham Vasculitis Activity Score version 3 (BVAS v. 3). In patients with HCV-CV the rate of sustained virologic (defined as undetectable HCV-RNA levels 12 weeks after treatment cessation) and immunological (defined as absence of circulating cryoglobulins, rheumatoid factor and normal C4 level) response; and the rate of complete (defined by a BVAS v. 3 score of 0) and partial (defined as BVAS v. 3 score <50% of the baseline score) clinical response were evaluated. Immunosupressants were given before or after DAAs therapy if clinically needed.Results. Median time of follow-up from treatment cessation were 26,5 (11,5–62,3) months. All 48 (100%) patients achieved sustained virologic response. Elimination of cryoglobulins were reported in 20 (41,7%) patients, complete immunological response-in 4 (8,3%) cases. Complete and partial clinical responses were observed in 13 (27,1%) and 19 (39,6%) patients, respectively. BVAS v. 3 score <4 at baseline was independently associated with complete clinical response (ОR=7,58; 95% CI: 1,42–40,48; р=0,018). 3 (6,3%) patients demonstrated HCV-CV relapse.Conclusion. Patients with HCV-CV require a long-term follow-up period even after reaching the SVR. The use of BVAS v. 3 score before the DAAs therapy can facilitate the planning of therapeutic approach, particularly, when identifying the patients in whom the immunosupressive therapy should be considered after viral eradication.
21 May 2026 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Aim: to conduct a comprehensive analysis of the clinical-genetic database of patients with Wilson’s disease and to evaluate the possibilities of using it as a tool for epidemiological and clinical research. Materials and methods. The study is based on data from 296 patients diagnosed with Wilson’s disease (WD), included in the clinical-genetic database for the period 2015–2025. The study involved a comprehensive assessment of results of clinical examinations of patients, including initial diagnosis and monitoring of their condition; laboratory test data, including molecular-genetic studies (performed using next generation sequencing and polymerase chain reaction); results of instrumental examinations. Results. The analysis of the clinical genetic database of patients with Wilson’s disease included data on 296 patients: 120 males and 176 females. The age of the study participants ranged from 14 to 67 years, with a mean age of 30.0 ± 6.5 years. Among the examined patients, 281 (94.94 %) individuals reside in the Russian Federation. Analysis of the distribution of patients by clinical forms of the disease revealed the following: abdominal form of WD was diagnosed in 140 (47.29 %) patients; neurological form — in 18 (6.09 %); mixed form — in 99 (33.45 %); asymptomatic form — in 39 (13.17 %) patients. When studying the characteristics of disease onset, it was found that 67 (22.63 %) patients had no pronounced clinical manifestations at the time of diagnosis. Among them, 17 patients (25.37 % of those with asymptomatic onset) were diagnosed through family screening. Molecular-genetic testing of the ATP7B gene was performed in 146 patients. Among the identified pathogenic variants, the most common was c.3207C>A (p.His1069Gln), detected in 114 (78.08 %) patients. The majority of patients (72.5 %) were compound heterozygotes, while rare variants of the ATP7B gene were found in 16.15 % of cases. Additionally, an analysis of course in WD patients who had COVID-19 was conducted. The results showed that 41.1 % experienced worsening of neurological symptoms. Furthermore, 9.8 % of patients with initially asymptomatic WD developed the first clinical manifestations of the disease after COVID-19 infection. Conclusions. The developed clinical-genetic database is an effective tool for studying WD, providing an informational basis for further epidemiological, clinical, and molecular genetic research.
15 February 2021 in Terapevticheskii arkhiv
ЯШЯнакаева Алиса Шамилевна
+4
Primary biliary cholangitis and sarcoidosis are both cholestatic liver diseases. Currently, there are no established specific criteria for distinguishing the diseases from each other; diagnosis is based on the anamnesis, as well as the results of physical, laboratory and instrumental examination. The case report presents a female patient with a rare combination of histologically verified liver sarcoidosis and primary biliary cholangitis. Despite the similar clinical manifestations, the approaches to the treatment of these diseases are completely different, that underlines the importance of the differential diagnosis to exclude combined liver damage.